menu search

Coherus to Acquire Surface Oncology

Coherus to Acquire Surface Oncology
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus’ I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs– – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over […] The post Coherus to Acquire Surface Oncology appeared first on ForexTV... Read More
Posted: Jun 16 2023, 11:01
Author Name: forextv
Views: 092084

Search within

Pages Search Results: